中国组织工程研究2014，Vol.18Issue(z1)：186-188,3.
贝伐单抗单药或联合伊立替康治疗复发性胶质母细胞瘤的Meta分析
王昀 1辛海 1党木仁1
作者信息
- 1. 新疆医科大学第一附属医院神经外科，新疆维吾尔自治区乌鲁木齐市 830011
- 折叠
摘要
Abstract
Meta-analysis evaluation method bevacizumab monotherapy and combination chemotherapy in recurrent glioblastoma efficacy and safety. <br> Computer database to retrieve the relevant domestic and foreign literature on control ed clinical trials of bevacizumab monotherapy and combination chemotherapy in recurrent glioblastoma are, according to the inclusion and exclusion criteria after screening and quality evaluation of the literature, using Cochrane Col aboration RevMan5 Meta-analysis software. <br> The study included 480 cases of patients, including bevacizumab group 183 cases (38.1%) and bevacizumab plus chemotherapy group 297 cases (61.9%) in the. Average and median overal survival was 8.63 months (95%CI=8.54-8.72) and 8.91 months (95%CI=8.69-9.13). The objective response rate (complete response+partial response rate) were 33.9% (95%CI=18.1-52.1) and 45.8%(95%CI=28.2-66.7). Progression-free survival of 6 months (PFS-6) was 38.8%(95%CI=18.8-57) and 48.3%(95%CI=25.4-54.3). Were 5.5%and 20%. Compared with patients treated with bevacizumab in bevacizumab plus irinotecan group had higher PFS-6 (P=0.046), objective response rate (P=0.013) and the discontinuation rate (P=0 ), the overal survival group (P=0.487) there was no statistical y significant difference. <br> Although bevacizumab in combination with chemotherapy can increase the withdrawal rate, but overal survival, objective response rate, progression-free survival rates were to rise, we can think of bevacizumab in combination with chemotherapy is safe and effective.关键词
贝伐单抗/伊立替康/胶质母细胞瘤/Meta分析Key words
bevacizumab/combined chemotherapy/glioblastoma/Meta analysis引用本文复制引用
王昀,辛海,党木仁..贝伐单抗单药或联合伊立替康治疗复发性胶质母细胞瘤的Meta分析[J].中国组织工程研究,2014,18(z1):186-188,3.
